<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141127">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01736683</url>
  </required_header>
  <id_info>
    <org_study_id>ACE-011-MDS-001</org_study_id>
    <nct_id>NCT01736683</nct_id>
  </id_info>
  <brief_title>Study of Sotatercept for the Treatment of Anemia in low-or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)</brief_title>
  <official_title>An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine a safe, tolerable and effective dose of
      sotatercept that results in the greatest frequency of improvement of anemia in patients
      diagnosed with low- or intermediate-1 risk MDS or non-proliferative chronic myelomonocytic
      leukemia (CMML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Following enrollment of the initial 3 arms; additional cohorts of 20 patients for
      intermediate cohorts (not to exceed 2.0 mg/kg) may be added at the time of dose escalation
      up to 1.0 mg/kg and up to 2.0 mg/kg (eg, 0.75 mg/kg or 1.5 mg/kg respectively) based on
      assessment by the Steering Committee of available safety and efficacy data when at least six
      subjects have at least three cycles of treatment in the current dose level.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Erythroid Hematological Improvement (HI-E)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>HI-E (for subjects that require a transfusion of &lt;4 units of RBCs) is an increase ≥1.5 g/dL Hgb sustained over a period ≥8 weeks in the absence of RBC transfusion; or HI-E (for subjects that require a transfusion of  ≥4 units of RBCs) is a decrease ≥4 units of RBCs transfused over a period of 8 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Event</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red Blood Cell (RBC) Transfusion Independence</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The time between randomization (for Part 1)/start of therapy (for Part 2) and the date the start of HI-E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration to Erythroid Hematological Improvement (HI-E)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The length of time between first and last assessment of HI-E</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression to Acute Myeloid Leukemia (AML)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time from baseline until progression to AML</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression to events of higher risk MDS</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time from baseline until progression to events of higher risk MDS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants who survive without progressing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Number of participants who survive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Cmax</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Maximum observed concentration in serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics-Tmax</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time to maximum observed concentration serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics- AUC</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Anemia</condition>
  <condition>Myelodysplastic Syndromes (MDS)</condition>
  <condition>Chronic Myelomonocytic Leukemia (CMML)</condition>
  <condition>Low to Intermediate-1 MDS</condition>
  <arm_group>
    <arm_group_label>Sotatercept 1.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotatercept 2.0 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sotatercept 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Sotatercept 1.0 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles</description>
    <arm_group_label>Sotatercept 1.0 mg/kg</arm_group_label>
    <other_name>(ActRIIA-IgG1Fc)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Sotatercept 2.0 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles</description>
    <arm_group_label>Sotatercept 2.0 mg/kg</arm_group_label>
    <other_name>(ActRIIA-IgG1Fc)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sotatercept</intervention_name>
    <description>Sotatercept 0.5 mg/kig subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles</description>
    <arm_group_label>Sotatercept 0.5 mg/kg</arm_group_label>
    <other_name>(ActRIIA-IgG1Fc)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Men and women ≥ 18 years of age

          -  Documented diagnosis of myelodysplastic syndromes (MDS) or non-proliferative chronic
             myelomonocytic leukemia (CMML), White blood cells (WBC) ≤ 13,000 /mm3, World Health
             Organization (WHO)) that meets International Prognostic Scoring System (IPSS)
             criteria for low or intermediate-1 risk disease

          -  Anemia defined as requiring transfusion of &gt;= 2 units of red blood cells (RBCs)
             within 84 days of enrollment for hemoglobulin (Hgb) &lt;= 9.0 g/dL

          -  No response or loss of response to Erythropoiesis-Stimulating Agents (ESAs) or
             erythropoetin (EPO) &gt; 500 mU/ml

          -  No response or loss of response to no greater than 2 prior lines of treatment for
             myelodysplastic syndromes (MDS) or non-proliferative chronic myelomonocytic leukemia
             (CMML) not including ESAs or lines discontinued due to intolerance.

          -  Eastern Cooperative Group (ECOG) score ≤2. Adequate renal function reflected by
             creatinine &lt; 1.5 X Upper Limit of the Normal (ULN) and creatinine clearance of 50
             ml/min according to Cockcroft-Gault formula

          -  Total bilirubin ≤3.0 mg/dL

          -  Aspartate aminotransferase (AST)/Serum glutamic oxaloacetic transaminase (SGOT) &amp;
             alanine aminotransferase (ALT)/serum glutamic pyruvic (SGPT) ≤3.0 x Upper Limit of
             Normal (ULN)

          -  Free of metastatic malignancy (other than myelodysplastic syndromes (MDS)) for ≥2
             years

        Exclusion Criteria:

          -  Pregnant or breast feeding women and males who do not agree to use condom during the
             sexual contact with females of childbearing potential.

          -  Major surgery within 30 days

          -  Incomplete recovery or incomplete healing of wounds from previous surgery

          -  Heart failure ≥3 (New York Heart Association(NYHA))

          -  Thromboembolic or myocardial infarction event within 6 months

          -  Subjects requiring ongoing anticoagulant therapy during course of study.  Aspirin is
             allowed.

          -  Concurrent  anti-cancer cytotoxic chemotherapy

          -  History of severe allergic or anaphylactic reaction or hypersensitivity to
             recombinant protein

          -  Known positive for human immunovirus (HIV) or infectious hepatitis type C or active
             infectious hepatitis type B.

          -  Clinically significant anemia unrelated to myelodysplastic syndromes (MDS)

          -  Thrombocytopenia (&lt;30,000/uL)

          -  Uncontrolled hypertension

          -  Treatment with another investigational drug or device within 28 days prior to Day 1

          -  Prior Exposure to sotatercept (ACE-011)

          -  Any serious medical condition, lab abnormality or psychiatric illness
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abderrahmane Laadem</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christopher Powell</last_name>
    <phone>908-673-2259</phone>
    <email>cpowell@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Rocky Mountain Cancer Centers</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute/Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>North Shore-LIJ Health System Monter Cancer Center</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The University of Texas, MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78681</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Star Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Hôpital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille -Hôpital Claude Huriez Service des Maladies du Sang</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU De Nantes</name>
      <address>
        <city>Nanes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris Cedex</city>
        <zip>75001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche en Cancerologie de Marseille- Institute Paoli Calmettes</name>
      <address>
        <city>Rouen</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen Cedex 1</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Purpan</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 24, 2014</lastchanged_date>
  <firstreceived_date>November 27, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACE-011</keyword>
  <keyword>anemia</keyword>
  <keyword>dose-ranging</keyword>
  <keyword>intermediate-1 risk myelodysplastic syndromes</keyword>
  <keyword>low risk myelodysplastic syndromes (MDS)</keyword>
  <keyword>multicenter</keyword>
  <keyword>open-label</keyword>
  <keyword>parallel</keyword>
  <keyword>phase 2</keyword>
  <keyword>randomized</keyword>
  <keyword>Sotatercept</keyword>
  <keyword>Non-proliferative chronic myelomonocytic leukemia (CMML)</keyword>
  <keyword>hemoglobin</keyword>
  <keyword>transfusions</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
